News

Weekly Policy Update: New Economic Forecast Indicates Increase in Expected Revenue Above the TABOR Cap

Thursday, June 20, 2019
 
Continue Reading

New State-of-the-Art Facility Increases Agilent's Capacity to Produce Nucleic Acid-Based Therapeutics

Tuesday, June 18, 2019

New facility in Frederick, Colorado, to produce high-quality molecules with the potential to treat cancer and other diseases 
Continue Reading

Pfizer to buy Colorado's Array BioPharma in deal worth $11.4 billion

Monday, June 17, 2019

Pharmaceutical giant Pfizer Inc. is delving deeper into cancer research with a roughly $11.4 billion deal for Array BioPharma Inc., a Colorado drug developer that has seen its shares soar since announcing positive clinical trial results earlier this spring.

Pfizer said Monday it will pay $48 per share in cash for Boulder-based Array, whose product portfolio includes a treatment combination used for advanced skin cancer that is being tested in other cancers as well.

Array said last month that its combination of the drugs Braftovi and Mektovi along with another treatment led to a significant improvement in overall survival in late-stage testing for some patients with colorectal cancer.

The company plans to submit results from that study to U.S. regulators for approval later this year.

Array's share price has jumped 41% since late May and more than doubled so far this year. Pfizer's offer of $48 per share represents a premium of 62% to the stock's closing price of $29.59 on Friday.

Shares of Array surged 60% before Monday's opening bell.

New York-based Pfizer, which makes the breast cancer drug Ibrance and the blood thinner Eliquis, said the boards of both companies have approved the deal.

It will finance the deal with debt and cash, and it expects the transaction to add to earnings per share starting in 2022.

Pfizer, the biggest U.S. drugmaker by revenue, has had several drug approvals in the U.S. or elsewhere so far this year. But it also saw a heavily touted pain drug flop in late-stage clinical testing, placing the drug's future in doubt.

Pfizer shares edged down 5 cents to $42.70 in premarket trading.

 
Continue Reading

Weekly Policy Update: CBSA Submits Comment Letter to Senate Finance Committee’s Health Task Force Urging Repeal of the Medical Device Excise Tax

Friday, June 14, 2019

 

CutisPharma Announces Acquisition of Silvergate Pharmaceuticals, Name Change to Azurity Pharmaceuticals

Thursday, June 13, 2019

WOBURN, Mass. (Jun. 12, 2019) – CutisPharma, Inc. announced today its acquisition of Silvergate Pharmaceuticals, Inc. and the unveiling of its new corporate brand for the unified company: Azurity Pharmaceuticals.
 

Weekly Policy Update: CBSA Attends the 2019 BIO International Convention

Monday, June 10, 2019

Last week CBSA President and CEO Jennifer Jones Paton and Vice President Emily Roberts attended the 2019 BIO International Convention in Philadelphia. The event brings together over 16,000 attendees from around the world for educational sessions, networking events, and partnering meetings. For the CBSA team, it’s a great opportunity to connect with industry partners, biotechnology companies, and other state associations to discuss collaboration opportunities and share best practices.  

Colorado BioScience Association Celebrates State’s Collaborative Nature

Monday, June 03, 2019

New Magazine Offers In-Depth Financing Data and Insights on Medical Device and Drug Approvals 
Continue Reading